Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080972 | 0.82 | SMARCA2 (0.59) | ALDH1A1MAPTSMARCA2SMARCA4 | |
| SCHEMBL320298 | 0.79 | MAPT (0.46) | ALDH1A1MAPTCOMTKDM4EHPGD | |
| SCHEMBL16545859 | 0.78 | FLT1 (0.45) | ALDH1A1MAPTCOMTKDM4EHPGD | |
| SCHEMBL23087900 | 0.77 | ALDH1A1 (0.54) | ALDH1A1MAPTCOMTKDM4EHPGD | |
| SCHEMBL15202358 | 0.77 | COMT (0.43) | ALDH1A1MAPTCOMTKDM4EHPGD | |
| SCHEMBL29915105 | 0.77 | ALDH1A1 (0.54) | ALDH1A1MAPTCOMTKDM4EHPGD | |
| SCHEMBL29790460 | 0.77 | COMT (0.43) | ALDH1A1MAPTCOMTKDM4EHPGD | |
| SCHEMBL28144654 | 0.77 | COMT (0.43) | ALDH1A1MAPTCOMTKDM4EADRA1A | |
| SCHEMBL2274673 | 0.77 | EGLN2 (0.44) | ALDH1A1MAPTCOMTKDM4EADRA1A | |
| SCHEMBL25258575 | 0.77 | IDO1 (0.44) | IDO1ALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| EP-1303509-B1 | BETA3 ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2012-11-28 | — | — | EP | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| US-7642358-B2 | Substituted phenylacetic acids | METABOLEX, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642358-B2 | Substituted phenylacetic acids | METABOLEX, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20040242633-A1 | Beta3 adrenergic agonists | EVERS BRITTA (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6730792-B2 | PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS | ELI LILLY AND COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20030191156-A1 | Beta3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2003-10-09 | — | — | US | disclosed |
| CN-1441800-A | β3Adrenergic agonists | LILLY CO ELI (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1303509-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | IDO1 714/4885ALDH1A1 1311/4885MAPT 4022/4885 |
| US-20030191156-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | IDO1 1006/4885ALDH1A1 1255/4885MAPT 1813/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | IDO1 3477/4885ALDH1A1 1369/4885MAPT 11/4885 |
| US-20040242633-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | IDO1 560/4885ALDH1A1 755/4885MAPT 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.